CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: John H Brebner, Karen B Green, MD, Richard Kaderman, PhD, Neil Love, MD, Michelle Paley, MD, Douglas Paley, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Ginelle Suarez, Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc and Genentech BioOncology. Research To Practice receives education grants from Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Genentech BioOncology/OSI Pharmaceuticals Inc, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Buzdar — Professor of Medicine; Deputy Chairman, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Consulting Fees: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Pfizer Inc, Roche Laboratories Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Pfizer Inc, Roche Laboratories Inc, Taiho Pharmaceutical Co Ltd. Dr Chlebowski — Professor of Medicine, David Geffen School of Medicine at UCLA; Chief, Medical Oncology, Harbor-UCLA Medical Center, Torrance, California. Consulting Fees: AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation, Pfizer Inc; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation. Dr Dickler — Assistant Attending Physician, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, New York. Consulting Fees: AstraZeneca Pharmaceuticals LP, Genentech BioOncology; Contracted Research: Genentech BioOncology; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: AstraZeneca Pharmaceuticals LP. Dr Ellis — Associate Professor of Medicine; Head, Section of Medical Oncology; Director, Breast Cancer Program; Co-Director, Translational and Clinical Research, Washington University School of Medicine, St Louis, Missouri. Consulting Fees: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals Corporation; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: GlaxoSmithKline; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Taiho Pharmaceutical Co Ltd. Dr Goss — Director of Breast Cancer Research, Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Consulting Fees and Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc. Dr Jahanzeb — Van Vleet Endowed Professor in Medical Oncology; Chief, Division of Hematology Oncology; Fellowship Program Director, University of Tennessee Health Science Center, Memphis, Tennessee. Contracted Research: Amgen Inc, Eli Lilly and Company, Genentech BioOncology, GlaxoSmithKline, Sanofi-Aventis; Speakers Bureau: Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Genentech BioOncology, GlaxoSmithKline, Sanofi-Aventis; Advisory Boards: AstraZeneca Pharmaceuticals LP, Easi Pharmaceuticals, Eli Lilly and Company, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Pfizer Inc. Dr Leyland-Jones— Vice President for Health Affairs and Director, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia. Consulting Fees: Abraxis BioScience, Genentech BioOncology, Pfizer Inc, Roche Laboratories Inc, VioQuest Pharmaceuticals Inc; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Genentech BioOncology, Roche Laboratories Inc; Contracted Research: Pfizer Inc, Roche Laboratories Inc, VioQuest Pharmaceuticals Inc. Dr Mackey — Medical Oncologist, Cross Cancer Institute; Professor, Medical and Experimental Oncology, University of Alberta; Chair of Research, Northern Alberta Breast Cancer Program; Director, Cancer International Research Group, Edmonton, Canada. Consulting Fees: Genentech BioOncology, Sanofi-Aventis; Other: Roche Laboratories Inc. Dr Pegram — Associate Professor of Medicine, David Geffen School of Medicine at UCLA; Director, Women’s Cancer Program, UCLA/Jonsson Comprehensive Cancer Center, Los Angeles, California. Consulting Fees: Genentech BioOncology, GlaxoSmithKline, Sanofi-Aventis. Dr Pritchard — Head, Clinical Trials and Epidemiology, Toronto Sunnybrook Regional Cancer Centre; Professor, Department of Medicine; Faculty of Medicine, University of Toronto, Toronto, Canada. Consulting Fees: AstraZeneca Pharmaceuticals LP, Roche Laboratories Inc. Dr Sparano — Professor of Medicine and Women’s Health, Albert Einstein College of Medicine; Associate Chairman, Department of Oncology, Montefiore Medical Center; Director, Breast Evaluation Center, Montefiore-Einstein Cancer Center, Bronx, New York. Consulting Fees: Genentech BioOncology, Sanofi-Aventis. Dr Winer — Director, Breast Oncology Center, Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts. Consulting Fees: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Merck and Company Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi-Aventis; Contracted Research: Genentech BioOncology, GlaxoSmithKline, Sanofi-Aventis.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.